Skip to main content

Table 1 Baseline characteristics of participants

From: Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: a phase I clinical trial

Subject

Age

Gender

Education, years

Medication

MMSE

ADAS-Cog

APOE genotype

Amyloid PET

LD_01

59

M

9

Donepezil 5 mg

21

19

e3/e4

Positive

LD_02

65

F

12

Donepezil 10 mg

26

19

e3/e3

Positive

LD_03

63

F

12

Donepezil 10 mg

25

16

e4/e4

Positive

HD_01

60

M

18

Donepezil 10 mg

18

20

e3/e4

Positive

HD_02

76

F

12

Donepezil 7.5 mg

17

27

e3/e3

Positive

HD_03

50

F

14

Rivastigmine 9.5 mg/24 h

14

29

e3/e3

Positive

HD_04

66

F

6

Memantine 10 mg, donepezil 10 mg

24

19

e3/e4

Positive

HD_05

53

F

16

Donepezil 10 mg

24

13

e3/e3

Positive

HD_06

73

M

12

Rivastigmine 9.5 mg/24 h

21

29

e4/e4

Positive

  1. LD, low dose; HD, high dose; AChE-I, acetylcholine esterase inhibitor; MMSE, Mini-Mental State Examination; ADAS-Cog, Alzheimer’s Disease Assessment Scale-Cognitive Subscale